JP2021505156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505156A5 JP2021505156A5 JP2020531046A JP2020531046A JP2021505156A5 JP 2021505156 A5 JP2021505156 A5 JP 2021505156A5 JP 2020531046 A JP2020531046 A JP 2020531046A JP 2020531046 A JP2020531046 A JP 2020531046A JP 2021505156 A5 JP2021505156 A5 JP 2021505156A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide according
- polypeptide
- antibody
- linker
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 102000000588 Interleukin-2 Human genes 0.000 claims 9
- 108010002350 Interleukin-2 Proteins 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 102100033635 Collectrin Human genes 0.000 claims 1
- 102100036966 Dipeptidyl aminopeptidase-like protein 6 Human genes 0.000 claims 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 1
- 102100030678 HEPACAM family member 2 Human genes 0.000 claims 1
- 101000945075 Homo sapiens Collectrin Proteins 0.000 claims 1
- 101000804935 Homo sapiens Dipeptidyl aminopeptidase-like protein 6 Proteins 0.000 claims 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 1
- 101000843667 Homo sapiens HEPACAM family member 2 Proteins 0.000 claims 1
- 101000923531 Homo sapiens Sodium/potassium-transporting ATPase subunit gamma Proteins 0.000 claims 1
- 101000612838 Homo sapiens Tetraspanin-7 Proteins 0.000 claims 1
- 108091006735 SLC22A2 Proteins 0.000 claims 1
- 108091006739 SLC22A6 Proteins 0.000 claims 1
- 102100034351 Sodium/potassium-transporting ATPase subunit gamma Human genes 0.000 claims 1
- 102100032417 Solute carrier family 22 member 2 Human genes 0.000 claims 1
- 102100036930 Solute carrier family 22 member 6 Human genes 0.000 claims 1
- 102100040952 Tetraspanin-7 Human genes 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595348P | 2017-12-06 | 2017-12-06 | |
| US201762595357P | 2017-12-06 | 2017-12-06 | |
| US62/595,348 | 2017-12-06 | ||
| US62/595,357 | 2017-12-06 | ||
| US201862675972P | 2018-05-24 | 2018-05-24 | |
| US15/988,311 | 2018-05-24 | ||
| PCT/US2018/034334 WO2018217989A1 (en) | 2017-05-24 | 2018-05-24 | Targeted immunotolerance |
| USPCT/US2018/034334 | 2018-05-24 | ||
| US15/988,311 US10676516B2 (en) | 2017-05-24 | 2018-05-24 | Targeted immunotolerance |
| US62/675,972 | 2018-05-24 | ||
| US201862721644P | 2018-08-23 | 2018-08-23 | |
| US16/109,897 US10174092B1 (en) | 2017-12-06 | 2018-08-23 | IL-2 muteins |
| US16/109,897 | 2018-08-23 | ||
| US16/109,875 US10174091B1 (en) | 2017-12-06 | 2018-08-23 | IL-2 muteins |
| US62/721,644 | 2018-08-23 | ||
| US16/109,875 | 2018-08-23 | ||
| PCT/US2018/062780 WO2019112852A1 (en) | 2017-12-06 | 2018-11-28 | Targeted immunotolerance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505156A JP2021505156A (ja) | 2021-02-18 |
| JP2021505156A5 true JP2021505156A5 (enrdf_load_stackoverflow) | 2022-01-06 |
Family
ID=66751175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531046A Abandoned JP2021505156A (ja) | 2017-12-06 | 2018-11-28 | 標的化免疫寛容 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3720871A4 (enrdf_load_stackoverflow) |
| JP (1) | JP2021505156A (enrdf_load_stackoverflow) |
| WO (1) | WO2019112852A1 (enrdf_load_stackoverflow) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| KR102684426B1 (ko) * | 2017-12-06 | 2024-07-11 | 팬디온 오퍼레이션스, 인코포레이티드 | Il-2 뮤테인 및 그 용도 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN114679909A (zh) | 2019-05-20 | 2022-06-28 | 潘迪恩运营公司 | MAdCAM靶向的免疫耐受 |
| EP4004025A1 (en) | 2019-07-26 | 2022-06-01 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| CN115023444A (zh) | 2019-12-20 | 2022-09-06 | 再生元制药公司 | 新型il2激动剂及其使用方法 |
| EP4087865A2 (en) | 2020-01-10 | 2022-11-16 | Bright Peak Therapeutics AG | Modified il-2 polypeptides and uses thereof |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| TW202237171A (zh) | 2020-12-04 | 2022-10-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| EP4366779A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Modified tnf-antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053354A2 (en) * | 2000-01-20 | 2001-07-26 | Chiron Corporation | Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules |
| ES2343518T3 (es) * | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | Polipeptidos interferon alfa modificados resistentes a proteasas. |
| PA8621301A1 (es) * | 2004-01-09 | 2006-09-22 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
| AU2005227263A1 (en) * | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| US10150802B2 (en) * | 2014-04-24 | 2018-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| WO2016164937A2 (en) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
| JP2020521452A (ja) * | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| US10174091B1 (en) * | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| KR102684426B1 (ko) * | 2017-12-06 | 2024-07-11 | 팬디온 오퍼레이션스, 인코포레이티드 | Il-2 뮤테인 및 그 용도 |
| WO2020061142A1 (en) * | 2018-09-18 | 2020-03-26 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
-
2018
- 2018-11-28 JP JP2020531046A patent/JP2021505156A/ja not_active Abandoned
- 2018-11-28 EP EP18887096.8A patent/EP3720871A4/en not_active Withdrawn
- 2018-11-28 WO PCT/US2018/062780 patent/WO2019112852A1/en not_active Application Discontinuation